Clinical trial · Interventional
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL
NCT00568815CI-TRIAL-00006299completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rituximab combined with ESHAP | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemo
- interventionNames
- Drug: Rituximab combined with ESHAP
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 6 weeks
Secondary outcomes (1)
- measure
- Toxicities
- timeFrame
- every cycle
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age range 18-70 years old * Histological confirmed diffuse large B cell lymphoma * ECOG performance status no more than 2 * Life expectancy of more than 3 months * Relapse or refractory after the first-line chemotherapy of DLBCL * No evidence of bone marrow involvement * Normal laboratory values: hemoglobin \> 8.0g/dl, neutrophil \> 1.5×109/L, platelet \> 80×109/L, serum creatine \< 1× upper limitation of normal(ULN), serum bilirubin \< 1× ULN, ALT and AST \< 1.5× ULN Exclusion Criteria: * Pregnant or lactating women * Serious uncontrolled diseases and intercurrent infection * The evidence of CNS metastasis and bone marrow involvement * History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * History of allergic reaction/hypersensitivity to rituximab
References
Publications (0)
Data not yet available
No reference posted for this study.